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Apheresis in Inflammatory Bowel 
Disease: Current Evidence
Balaban Daniel Vasile and Mariana Jinga
Abstract
Inflammatory bowel diseases (IBD) have become a major focus for gastroenter-
ologists worldwide, with the increasing incidence and complexity of cases, which 
pose therapeutic challenges. Currently available approaches fail in controlling the 
disease activity in a significant proportion of patients and some of the therapies are 
associated with significant adverse events. Although new molecules are on the hori-
zon and treatment strategies have been optimized, novel therapeutic tools are much 
needed in IBD for patients who fail to attain control of the disease. Apheresis is now 
a common non-pharmacological therapeutic modality used in several pathologies, 
IBD also. In the current review, we summarize currently available evidence with 
respect to selective apheresis in IBD.
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, apheresis, 
leukapheresis
1. Introduction
Inflammatory bowel diseases (IBD), comprising ulcerative colitis (UC) and 
Crohn’s disease (CD), are chronic inflammatory conditions of the digestive tract 
with a relapsing-remitting course, which can dramatically decrease patients’ quality 
of life. With a steadily increasing incidence worldwide [1] and with the growing 
needs and demands from patients, IBD have become a major focus for the gastro-
enterology community, both practitioners and researchers. Over the last decades, 
management of IBD has improved considerably, but is quite far from being satisfac-
tory for a significant number of patients. Currently, the therapeutic armamentar-
ium includes several drug regimens, endoscopic therapies, and surgery. Despite the 
development of novel targeted molecules and optimization of treatment strategies 
in IBD, some patients fail to achieve disease control with currently available treat-
ment options. Moreover, drug-based therapies are associated with significant 
adverse events and contraindications, which may lead to treatment discontinuation 
or even refusal of therapy. Not least, chronic use of conventional therapies is associ-
ated with loss of response, which can pose challenges in the long-term control of the 
disease. In this setting, novel therapeutic approaches have been searched for by the 
scientific community and apheresis has emerged as a promising non-pharmacologic 
treatment option in IBD.
Although guidelines are not frequently reporting it [2], several successful 
experiences have been reported so far in the literature. In this chapter, we will sum-
marize current evidence regarding apheresis in IBD.
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2. Principles of apheresis in IBD
Apheresis techniques are being used in many medical specialties, from nephrol-
ogy and intensive care to gastroenterology. It consists of depleting the patient’s 
blood from certain components (cells, cytokines, or other molecules) depending 
of the filter used and the indication. Its applications in digestive pathology include 
alcoholic hepatitis [3], hepatitis C-associated cryoglobulinemia [4], hypertriglyceri-
demia-induced acute pancreatitis [5], and IBD.
IBD is undoubtedly characterized by complex pathogenesis, but leucocytes play 
a key role in driving the bowel inflammation. Most of the conventional treatments 
in IBD address the proinflammatory cytokines released by the activated leucocytes, 
while apheresis acts by extracting the white cells (specifically a subset of WBCs) 
from the patient’s blood, either by centrifugation or by passing the blood through an 
adsorptive device. Initially, centrifugation was used to deplete the activated leuko-
cytes from the patient’s blood; this reduction in the number of WBCs proved benefi-
cial for IBD patients but had limitations generated from the nonspecific removal of 
leukocytes. To overcome these limitations, columns containing membrane filters or 
adsorbing beads have been developed to selectively remove the desired level of WBCs.
Regarding the use of apheresis in IBD, its benefits reside from depleting the 
blood from certain subtypes of leucocytes, which migrate into the bowel wall and 
fuel the local inflammatory response. This selective removal of specific white 
cells—mostly granulocytes and monocytes—is being regarded as a technique of 
extracorporeal immunomodulation, with proven benefits for IBD patients; besides 
this selective depletion of granulocytes and monocytes/macrophages, several other 
beneficial changes in the inflammatory cascade of IBD patients have been reported 
and could contribute to the efficacy of apheresis in IBD [6].
A schematic description of leukocyte apheresis in IBD is represented in Figure 1— 
the patients’ blood is passed through a filter which selectively removes white cells 
(mainly granulocytes and monocytes) and then returned to the patient’s body; the 
resulting blood has fewer leukocytes and in turn there are (?) less of them to fuel the 
inflammation in the bowel wall. As for other extracorporeal machines, anticoagulation 
is used during leukapheresis for IBD.
First reports of apheresis in IBD date back from 1980s [7], when centrifugal leu-
kocytapheresis was used in patients with Crohn’s disease. With this technique, the 
patient’s blood was depleted by about 55% of lymphocytes, 40% of granulocytes, 
and a significant amount of red blood cells and platelets [6].
Subsequent models for apheresis incorporated a filter or a column for the 
selective removal of certain blood components. Currently, there are two leukocyte 
adsorptive devices available for apheresis in IBD patients [6, 8]:
• Adacolumn (Japan Immunoresearch Laboratory, Japan), a granulocyte/mono-
cyte apheresis (GMA) system which consists of a column filled with cellulose-
coated acetate beads that selectively remove granulocytes and monocytes 
through binding of FCγR (Fc gamma receptor—a receptor for the Fc portion 
of IgG), and to a lesser extent lymphocytes, as they do not express FCγR [9]. 
The device adsorbs 65% of granulocytes, 55% of monocytes, and only 2% 
of lymphocytes and few platelets [10]. Patients usually undergo one or more 
sessions per week up, according to different protocols.
• Cellsorba (Asahi Medical, Japan), a leukocyte apheresis (LCAP) system 
represented by a column containing non-woven polyester fibers, which retain 
leucocytes as follows: 90–100% of granulocytes and monocytes, 30–60% of 
lymphocytes, and a certain amount of thrombocytes [11, 12].
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3. Leukapheresis in IBD
Leukocyte apheresis (leukapheresis) has been evaluated in several trials as a 
treatment option in patients with steroid-dependent or steroid-refractory UC/
CD and in moderate-severe disease unresponsive to conventional therapy. The 
standard protocol implies that the patient has one apheresis session (60 minutes 
duration) per week for 5–10 consecutive weeks, but others have proposed modified 
protocols with more intensive therapy (2 sessions per week, 90 minutes duration). 
Common adverse reactions include dizziness, headache, and mild, transient fever. 
The procedure has a good safety profile and is usually well tolerated. Leukapheresis 
allows IBD patients to taper or even get off steroids and to achieve earlier remission 
[13]. Besides patients with steroid-dependent and steroid-refractory disease, it has 
proven efficacious in steroid-native patients also. A major issue of leukapheresis is 
cost, but considering the elimination of the need for steroids and their complica-
tions and the need for hospitalization for flaring, this non-pharmacologic technique 
may be cost-effective for selected patient categories [14]. A selection of studies 
reporting its efficacy and safety is presented in Tables 1 and 2.
Most of the above papers report on the efficacy and safety of apheresis 
techniques in difficult to treat patient categories—steroid-dependent/-resistant 
or refractory to conventional treatment, UC being studied more than CD. 
However, while early observational studies have reported very high response 
or remission rates (up to 80%) in these difficult to treat patients, a randomized 
controlled trial comparing GMA to sham (placebo) showed much lower remis-
sion rates and no significant differences between the compared groups than in 
previous studies [36].
Figure 1. 
Schematic representation of apheresis in IBD.
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Author, year Indication No. of patients Overall response 
rate
Adverse 
events 
(number  
or %)
Shimoyama  
et al., 2001 [15]
UC (refractory 
to conventional 
treatment)
53 58.5% of patients 
had remission or 
improved
9.4%—8 
non-severe 
AE (in 5 
patients)
Tomomasa  
et al., 2003 [16]
Pediatric UC 
(steroid-refractory)
12 67% improvement 9%
Hanai et al., 
2003 [17]
UC 31 
steroid-refractory
8 steroid naive
81% remission 
in steroid-
refractory, 88% in 
steroid-naive
18%
Matsui et al., 
2003 [18]
CD (refractory 
to conventional 
treatment)
7 71.4%
Hanai et al., 
2004 [19]
UC 
(steroid-dependent)
46 83% remission at 
week 12
21.7% (10 
mild AE)
Suzuki et al., 
2004 [20]
UC (steroid-naive) 20 85% remission 10%
Kusaka et al., 
2004 [21]
CD (un-responsive 
to conventional 
treatment)
6 66.6%
Fukuda et al., 
2004 [22]
CD (moderate-severe, 
unresponsive to 
standard therapy)
21 52.4%
Naganuma et 
al., 2004 [23]
UC (steroid-refractory 
or -dependent)
44 55% remission 
+ 20% clinical 
response
5%
Yamamoto  
et al., 2004 [24]
UC (mild-moderate) 30 70% clinical 
remission
27% (in 8 
patients, 9 
sessions)
Domenench 
2004 [25] 
UC and CD 14 (13*) UC, 12 
(10*) CD
62% remission in 
UC, 70% in CD
4
Kanke et al., 
2004 [26]
UC (mild to severe) 60 23% remission, 
60% improvement
18%
Kim et al.,  
2005 [27]
UC (refractory 
to conventional 
treatment)
27 70% improvement 11%
Kruis et al., 
2005 [28]
UC 39 (35*) 37.1% clinical 
remission and 
28.6% endoscopic 
remission
1
D’Ovidio et al., 
2006 [29]
UC (mild-moderate, 
steroid dependent/
refractory)
12 75% clinical 
response
None
Ikeda et al., 
2006 [30]
Pediatric UC 4 75%
Sands et al., 
2006 [31]
IBD 15 UC, 15 CD Response—45.5% 
UC, 64.3% CD
No SAE
Muratov et al., 
2006 [32]
IBD (relapse 
or refractory to 
conventional 
treatment)
10 (7 CD, 3 UC) 50% remission No SAE
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Author, year Indication No. of patients Overall response 
rate
Adverse 
events 
(number  
or %)
Ljung et al., 
2007 [33]
UC, CD, and 
indeterminate 
colitis (mostly 
steroid-refractory or 
steroid-dependent)
100 69% remission or 
response
15
Yamamoto et 
al., 2007 [34]
UC 50 52% clinical 
remission, 34% 
endoscopic 
remission
Bresci et al., 
2007 [35]
UC 40 70% clinical 
response
1
Sands et al., 
2008 [36]
UC (moderate-severe) 169 17% clinical 
remission in GMA-
group (vs 11% 
sham-treatment 
group)
—
Maiden et al., 
2008 [37]
UC and CD 29 72.4% clinical 
remission at 
6 months
55% mild 
and transient 
headache
No SAE
Hanai et al., 
2008 [38]
UC (moderate or 
severe)
70 (35 
randomized to 
Adacolumn)
74.3% clinical 
remission at 
12 weeks
5 mild AE
2 
discontinued
Tanaka et al., 
2008 [39]
UC 45 73.3% clinical 
remission
No SAE
Transient 
flushing 
and light-
headedness 
in few 
patients
Sakata et al., 
2008 [40]
UC (moderate-severe) 39 randomized 
(17 Adacolumn, 
21 Cellsorba)
76.5% clinical 
improvement 
in Adacolumn-
group, 66.7% in 
Cellsorba-group
No SAE
de Carpi et al., 
2008 [41]
Pediatric IBD 9 (5 UC, 4 CD) 55.5% remission No SAE
Hibi et al., 2009 
[42]
UC (severe, refractory 
to conventional 
medications)
697 77.3% 7.7% mild-
moderate
No SAE
Sakuraba et al., 
2009 [43]
UC (mild-to-
moderately active UC)
163 Clinical 
remission—54.0% 
in weekly GMA 
and 71.2% in 
intensive GMA
No GMA-
related SAE
Cabriada et al., 
2010 [44]
UC 
(steroid-dependent)
18 (Cellsorba—2, 
Adacolumn—16)
55% clinical 
remission 
(induction), 
50% endoscopic 
remission
None
Yamamoto et 
al., 2010 [45]
UC (endoscopically 
active)
124 45% clinical 
remission
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Author, year Indication No. of patients Overall response 
rate
Adverse 
events 
(number  
or %)
Lindberg et al., 
2010 [46]
IBD (unresponsive 
to conventional 
treatment)
15 UC, 25 CD 85% clinical 
response, 
65% complete 
remission
6 AE
No SAE
Bresci et al., 
2010 [47]
Refractory CD 16 63.3% clinical 
remission
No SAE
D’Ovidio et al., 
2011 [48]
UC (steroid 
dependent/refractory)
69 58% responders 2 mild, 1 
transient 
arrhythmia
Cabriada et al., 
2012 [49]
UC 
(steroid-dependent)
142 41% remission 
at 6 months, 
36% remission at 
12 months
1 SAE
Yokoyama et 
al., 2013 [50]
UC 43 53.5% clinical 
remission rate
No SAE
Sacco et al., 
2013 [51]
IBD 118 (83 UC, 35 
CD)
71% UC clinical 
remission, 63% 
CD
Fukuchi et al., 
2014 [52]
CD 22 81.8% clinical 
remission at 
52 weeks
No SAE
Yoshimura et 
al., 2015 [53]
CD (moderate-severe) 104 Remission—35.6% 
in weekly GMA, 
35.2% in intensive 
GMA
22.2%
Tanida et al., 
2015 [54]
Refractory UC 9 55.6% cumulative 
clinical remission 
at 10 weeks
3
Kruis et al., 
2015 [55]
UC 168 (165*—68 
with microscopic 
erosion/
ulceration)
23.9% remission 
with GMA vs. 0% 
sham
Dignass et al., 
2016 [56]
UC (steroid-
dependent, moderate-
to-severe, with 
insufficient response 
or intolerance to 
immunosuppressants 
and/or biologics)
86 39.3% clinical 
remission, 56% 
clinical response
Majority 
mild-
moderate
Ruuska et al., 
2016 [57]
Pediatric UC 25 45% significant 
improvement, 
25% moderate 
improvement
21 AE in 8/25 
(32%), no 
SAE
Imperiali et al., 
2017 [58]
UC (moderate, 
steroid-dependent, 
azathioprine-
intolerant/
resistant)
33 36% steroid-free 
clinical remission 
at 1 year +9% 
clinical response
1
Lai et al., 2017 
[59]
UC 34 70.59% overall 
efficacy
No GMA-
related SAE
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Author, year Indication No. of patients Overall response 
rate
Adverse 
events 
(number  
or %)
Motoya et al., 
2019 [60]
UC and CD 437 46.4% clinical 
remission in UC, 
33.3% in CD
11.4%
Overall response rate—response + remission rate.
GMA—granulocyte and monocyte/macrophage apheresis, AE—adverse events, SAE— severe adverse events,  
UC—ulcerative colitis.
*Number of patients included in the final analysis.
Table 1. 
Summary of studies reporting the efficacy of Adacolumn in IBD.
Author, year Indication No of patients Overall response rate Adverse 
events 
(number 
or %)
Kosaka et al., 
1999 [61]
CD (refractory 
to conventional 
treatment)
18 50%
Sawada et al., 
1995 [62]
Both UC and CD 44 (25 UC, 19 
CD)
Clinical 
improvement—85% in 
UC, 84.2% in CD
Sawada et al., 
2003 [63]
UC 39 74% 28%
Sawada et al., 
2005 [64]
UC (moderate-to-
severe)
25 (9 excluded; 
10 randomized to 
active-group, 9 
sham)
80% clinical improvement 1
Sawada et al., 
2005 [65]
UC with toxic 
megacolon
6 66.7% improved, 33.3% 
colectomy
Nishioka et 
al., 2005 [66]
UC 29 (9 LCAP, 20 
cortisone)
88.9% clinical 
improvement, 35% 
remission
No major 
AE
Takemoto et 
al., 2007 [67]
UC 
(steroid-resistant)
71 75% initial response, 27% 
maintained remission 
>6 months
4%
Emmrich et 
al., 2007 [68]
UC (refractory 
to conventional 
treatment)
20 70% clinical remission
Shimada et 
al., 2008 [69]
UC (moderate-to-
severe)
10 80% clinical remission None
Yokoyama et 
al., 2014 [70]
UC 847 (623*) 68.9% overall clinical 
remission, 62.5% mucosal 
healing
10.3% 
of which 
0.6% 
severe
Kobayashi et 
al., 2018 [71]
UC 314 63.6% 1-year cumulative 
relapse-free rate, 
85.1% response rate in 
re-treatment
Overall response rate—response + remission rate.
AE—adverse events, SAE—severe adverse events.
*Number of patients included in the final analysis.
Table 2. 
Summary of studies reporting the efficacy of Cellsorba in IBD.
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Along with the observational nature of most studies on apheresis in IBD, 
another important limit is that many of them were conducted in the era before bio-
logics and novel oral therapies for IBD, when patients did not have so many options 
when failing steroids. While early studies evaluated the efficacy of apheresis as 
monotherapy in refractory IBD, more recent ones have proposed combination 
therapy of biologics with adsorptive apheresis, with promising results [72]. Also, 
recent studies have shown good results not only in induction of remission but also 
as maintenance therapy [73].
Not least, another limitation is that a significant proportion of studies report 
on small sample sizes, with very heterogeneous study groups with regard to sever-
ity and extent of disease, which limit on extrapolation of the results in all patient 
categories. There are some studies on special patient populations such as the elderly 
and pediatric/adolescent patients, in whom adverse reactions of conventional 
therapy can be more severe or even contraindicate their use [60].
With regard to safety, most of the adverse effects reported were mild and 
transient (such as fever, headache, flushing, and dizziness), very rarely severe 
adverse events. Despite being an invasive procedure, a study looking at the patients’ 
perspective found that GMA is well accepted by patients suffering from IBD [74]. 
This is very encouraging considering that up to one in two patients encounter side 
effects with conventional therapies [15].
Regarding the type of anticoagulant used for the extracorporeal circulation of the 
blood during the apheresis session, there is one comparative study looking at nafamo-
stat mesilate versus heparin, the latter being associated with a lower rate of AE [75].
In order to improve the outcome and safety of the procedure, some authors have also 
looked at the optimal apheresis treatment volume, showing that using a bodyweight 
adjusted volume is associated with similar therapeutic efficacy but with less AE [76].
Considering the current evidence, with the wide range of results from very 
heterogeneous studies, the upcoming research should focus on establishing mark-
ers to appropriately select IBD patients that would safely and cost-effective benefit 
from apheresis techniques [77].
Besides GMA and LCAP, novel apheresis techniques are being studied in IBD 
such as leucocyte/thrombocyte apheresis system, which showed promising results 
in a small prospective, randomized, controlled multicenter pilot study [78].
4. Conclusions
While leukocyte-derived proinflammatory cytokines have been validated as 
successful targets in IBD treatment, so should leukocytes themselves be considered 
as treatment options. As activated leukocytes migrate into the bowel wall and drive 
the inflammatory cascade in IBD patients, their depletion by apheresis techniques 
are considered beneficial to control the mucosal inflammation.
Leukapheresis, consisting in either granulomonocyte apheresis or leukocyte 
apheresis, are cell-based therapies with promising results in some patient categories 
and with a good safety profile. They have been studied as an alternative in patients 
with steroid toxicity, dependency or refractoriness, or in the event of contraindica-
tions to conventional therapy. Most of the early studies were not controlled, with 
only a few randomized controlled trials providing quality data on their efficacy. 
Future studies should be designed to look at selection of IBD patients who benefit 
most and safely from this non-pharmacological therapy.
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